Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOM230 in Acute Cluster Headache
NCT02619617Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2016
- Primary completion
- Sep 2018
- Modality
- Peptides, Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of pasireotide LAR in Cluster Headache (CH), sponsored by Novartis. Started Oct 2016; status: terminated.
02
Drugs
pasireotide LAR
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on NCT02619617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02619617.